Rege Nephro completed the acquisition of Tamibarotene-related assets from Syros Pharmaceuticals.

Synopsis

Rege Nephro, a biopharmaceutical company, completed the acquisition of Tamibarotene-related assets from Syros Pharmaceuticals, a biotechnology company. Financial terms were not disclosed.

Principals

target

Syros Pharmaceuticals (tamibarotene-related Assets)

bidder

Rege Nephro

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context